AXOGEN INC. - COMMON STOCK

Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)

03 сен 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. Announces New Leadership Appointments

08 авг 2024 04:05:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. Reports Second Quarter 2024 Financial Results

08 авг 2024 04:00:01 Источник Nasdaq GlobeNewswire

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

23 июл 2024 04:00:00 Источник Nasdaq GlobeNewswire

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

01 июл 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

24 июн 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

28 май 2024 13:30:00 Источник Nasdaq GlobeNewswire

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

16 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

14 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc Reports First Quarter 2024 Financial Results

02 май 2024 04:00:01 Источник Nasdaq GlobeNewswire

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

29 апр 2024 13:50:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

16 апр 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

05 мар 2024 04:00:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

13 фев 2024 13:30:00 Источник Nasdaq GlobeNewswire

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

02 фев 2024 13:15:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

18 янв 2024 14:00:00 Источник Nasdaq GlobeNewswire

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

04 янв 2024 13:45:00 Источник Nasdaq GlobeNewswire

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

04 янв 2024 13:40:00 Источник Nasdaq GlobeNewswire

Axogen Announces Promotions on Research and Development Team

04 янв 2024 13:35:00 Источник Nasdaq GlobeNewswire

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

26 дек 2023 13:15:00 Источник Nasdaq GlobeNewswire